Evotec SE header image

Evotec SE

EVT

Equity

ISIN DE0005664809 / Valor 505433

Xetra (2026-04-24)
EUR 5.35-0.93%

Evotec SE
UMushroom community rating:

star star star star star
4.29 7 votes No rating yet
NegativeNeutralPositive

About company

Evotec SE is a global drug discovery and development partnership company headquartered in Germany, specializing in providing integrated solutions to the pharmaceutical and biotechnology industries. The company leverages its extensive expertise in areas such as medicinal chemistry, biology, and data science to support the development of new therapeutics across various therapeutic areas, including neuroscience, oncology, and metabolic diseases. Evotec collaborates with a diverse range of partners, including major pharmaceutical companies, biotech firms, and academic institutions, to advance innovative drug candidates from early discovery through clinical development. In the first quarter of 2025, Evotec reported progress in strategic partnerships and the implementation of initiatives aimed at achieving sustainable and profitable growth, reinforcing its position as a key player in the biopharmaceutical landscape.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results ():

Summarized from source with an LLMView Source

Key figures

-27.2%1Y
-69.9%3Y
-84.0%5Y

Performance

58.7%1Y
67.2%3Y
59.2%5Y

Volatility

Market cap

1113 M

Market cap (USD)

Daily traded volume (Shares)

733,229

Daily traded volume (Shares)

1 day high/low

8.73 / 8.45

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

4.29

7 votes
Performance:
starstarstarstarstar
4.29
Innovation:
starstarstarstarstar
4.29
Society:
starstarstarstarstar
4.00
Nature:
starstarstarstarstar
3.86
Meret Jaggi
Switzerland, 30 May 2022
star star star star star
Oliver Moon
Switzerland, 30 May 2022
star star star star star
German biotech/ pharma company. Decent upside potential. Analyst buy. Good performance history. Seems good to me.
Atanas WI Atanasov
Switzerland, 30 May 2022
star star star star star

EQUITIES OF THE SAME SECTOR

Smith & Nephew PLC
Smith & Nephew PLC Smith & Nephew PLC Valor: 1111046
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.10%USD 31.57
Addus HomeCare Corp
Addus HomeCare Corp Addus HomeCare Corp Valor: 10385048
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.32%USD 95.71
Sareum Holdings PLC
Sareum Holdings PLC Sareum Holdings PLC Valor: 116566624
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.38%GBP 0.20
Summit Therapeutics Inc
Summit Therapeutics Inc Summit Therapeutics Inc Valor: 56903013
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.85%USD 22.08
Acadia Healthcare Co Inc
Acadia Healthcare Co Inc Acadia Healthcare Co Inc Valor: 14151414
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.15%USD 27.38
Healthcare Services Group Inc
Healthcare Services Group Inc Healthcare Services Group Inc Valor: 938239
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.99%USD 22.42
Straumann Holding Ltd
Straumann Holding Ltd Straumann Holding Ltd Valor: 117544866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.10%CHF 84.52
Ultragenyx Pharmaceutical Inc
Ultragenyx Pharmaceutical Inc Ultragenyx Pharmaceutical Inc Valor: 22860122
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-0.74%USD 24.10
Viatris Inc
Viatris Inc Viatris Inc Valor: 58198423
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.08%USD 14.59
Ypsomed Holding AG
Ypsomed Holding AG Ypsomed Holding AG Valor: 1939699
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.07%CHF 281.40